ClinicalTrials.Veeva

Menu
N

New England Retina Consultants | Retina Research Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
CU06-1004
AVD-104
methotrexate
APL-2
Triamcinolone Acetonide
Tarcocimab
ADX-2191
AXT107

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 13 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad
Locations recently updated

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: AXT107 Mid Dose
Drug: AXT107 High Dose

Trial sponsors

Kodiak Sciences logo
Aldeyra Therapeutics logo
A
A
A
C
C
Genentech logo
N
Optos logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems